11![JOB DESCRIPTION – Associate Director/Director, Clinical Development Operations A. Organization The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologis JOB DESCRIPTION – Associate Director/Director, Clinical Development Operations A. Organization The Parker Institute for Cancer Immunotherapy is an unprecedented collaboration between the country’s leading immunologis](https://www.pdfsearch.io/img/621a52482591244f7bc07244f3e07025.jpg) | Add to Reading ListSource URL: www.parkerici.org- Date: 2016-12-09 15:56:02
|
---|
12![Immunotherapy Combinations TRANSCRIPT & FIGURES ©2015 GRACE - All Rights Reserved cancerGRACE.org Immunotherapy Combinations TRANSCRIPT & FIGURES ©2015 GRACE - All Rights Reserved cancerGRACE.org](https://www.pdfsearch.io/img/353bda00e186e9ebc78c32345545ad1a.jpg) | Add to Reading ListSource URL: cancergrace.org- Date: 2016-04-26 18:44:02
|
---|
13![12th International Workshop IMMUNOTHERAPY 2016 Hotel Nacional de Cuba / October 17‐21, Havana, Cuba REGISTRATION FORM Please complete one registration form per participant, including accompanying persons not att 12th International Workshop IMMUNOTHERAPY 2016 Hotel Nacional de Cuba / October 17‐21, Havana, Cuba REGISTRATION FORM Please complete one registration form per participant, including accompanying persons not att](https://www.pdfsearch.io/img/bfb1eefae6f3b94982229ea4a61e2842.jpg) | Add to Reading ListSource URL: www.immunotherapy.cim.co.cu- Date: 2016-08-03 09:55:42
|
---|
14![Building a world-class specialty biopharmaceutical business Interim report and accounts 2015
Contents 01 Introduction from the Chief Executive Building a world-class specialty biopharmaceutical business Interim report and accounts 2015
Contents 01 Introduction from the Chief Executive](https://www.pdfsearch.io/img/073136059fbd39138b77688c3768e5cd.jpg) | Add to Reading ListSource URL: www.circassia.comLanguage: English - Date: 2015-11-05 09:21:40
|
---|
15![20160404_Anergis_Closes_CHF_5_Million_Financing_Round_Extension_to_Conduct_the_ATIBAR_Trial 20160404_Anergis_Closes_CHF_5_Million_Financing_Round_Extension_to_Conduct_the_ATIBAR_Trial](https://www.pdfsearch.io/img/7332747049b4111e077d9ec410598708.jpg) | Add to Reading ListSource URL: www.biomedvc.comLanguage: English - Date: 2016-04-04 05:01:38
|
---|
16![VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develo](https://www.pdfsearch.io/img/ee83b95865f7addaac134e669b06c41f.jpg) | Add to Reading ListSource URL: sunstone.euLanguage: English - Date: 2016-07-12 04:22:18
|
---|
17![Cover Conference-at-a-Glance Final Agenda Eighth Annual Cover Conference-at-a-Glance Final Agenda Eighth Annual](https://www.pdfsearch.io/img/db0641051ebee87c5a45c8e80a62ec6e.jpg) | Add to Reading ListSource URL: www.giievent.jpLanguage: English - Date: 2016-08-16 03:53:14
|
---|
18![F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci F-star announces funding and collaboration extension with new Christian Doppler Lab for Innovative Immunotherapeutics Strong academic bridge supports F-star’s leading, innovative position in immuno-oncology and bispeci](https://www.pdfsearch.io/img/dd990034e991803baaddf571ff99170d.jpg) | Add to Reading ListSource URL: www.f-star.comLanguage: English - Date: 2016-07-13 10:00:22
|
---|
19![17427_UKW_AG-Bumm_Postdoc.cdr 17427_UKW_AG-Bumm_Postdoc.cdr](https://www.pdfsearch.io/img/faaa2bfd910d3e5f57ce558df960f53e.jpg) | Add to Reading ListSource URL: www.labtimes.orgLanguage: English - Date: 2016-08-05 06:11:11
|
---|
20![PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell](https://www.pdfsearch.io/img/a08b8ab67bd73501db5565370b38f386.jpg) | Add to Reading ListSource URL: www.immunocore.comLanguage: English - Date: 2016-03-29 05:35:06
|
---|